Jazz Pharmaceuticals PLC

자세한 내용은 Jazz Pharmaceuticals PLC 회사

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

회사 정보

종목 코드 JAZZ

회사 이름Jazz Pharmaceuticals PLC

상장일Jan 18, 2012

CEOMs. Renee D. Gala

직원 수2800

유형Ordinary Share

회계 연도 종료Jan 18

주소Fifth Floor, Waterloo Exchange

도시DUBLIN

증권 거래소NASDAQ Global Select Consolidated

국가Ireland

우편 번호- -

전화35316347800

웹사이트https://www.jazzpharma.com/

종목 코드 JAZZ

상장일Jan 18, 2012

CEOMs. Renee D. Gala

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Seamus C. Mulligan

Independent Director

1.27M

+8.67%

Mr. Bruce C. Cozadd

Chairman of the Board

335.96K

-0.30%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Ms. Renee D. Gala

President, Chief Executive Officer, Director

29.39K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

27.68K

--

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

--

Dr. Norbert G. Riedel, Ph.D.

Independent Director

12.22K

--

Ms. Anne O'Riordan

Independent Director

11.07K

--

Mr. Rick E. Winningham

Lead Independent Director

8.96K

--

이름

이름/직위

직위

주식 보유

변동

Mr. Seamus C. Mulligan

Independent Director

1.27M

+8.67%

Mr. Bruce C. Cozadd

Chairman of the Board

335.96K

-0.30%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.28K

--

Ms. Renee D. Gala

President, Chief Executive Officer, Director

29.39K

--

Mr. Kenneth W. (Ken) O'Keefe

Independent Director

27.68K

--

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

21.63K

-15.90%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

Xywav

344.80M

38.40%

Epidiolex/epidyolex

217.74M

24.25%

Rylaze

94.23M

10.50%

Zepzelca

63.03M

7.02%

High-sodium oxybate AG royalty revenue

48.95M

5.45%

Other

129.09M

14.38%

지역별USD

이름

수익

비율

United States

797.95M

88.87%

Europe

83.61M

9.31%

All Others

16.29M

1.81%

사업별

지역별

사업별USD

이름

수익

비율

Xywav

344.80M

38.40%

Epidiolex/epidyolex

217.74M

24.25%

Rylaze

94.23M

10.50%

Zepzelca

63.03M

7.02%

High-sodium oxybate AG royalty revenue

48.95M

5.45%

Other

129.09M

14.38%

주식 보유 통계

마지막 업데이트: Tue, Jul 22

주주

주주 유형

주주

비율

The Vanguard Group, Inc.

9.91%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.08%

Dimensional Fund Advisors, L.P.

3.85%

State Street Global Advisors (US)

3.25%

Other

70.31%

주주

비율

The Vanguard Group, Inc.

9.91%

BlackRock Institutional Trust Company, N.A.

8.61%

LSV Asset Management

4.08%

Dimensional Fund Advisors, L.P.

3.85%

State Street Global Advisors (US)

3.25%

Other

70.31%

주주 유형

주주

비율

Investment Advisor

53.78%

Investment Advisor/Hedge Fund

31.14%

Hedge Fund

9.59%

Research Firm

3.30%

Individual Investor

3.06%

Pension Fund

2.14%

Bank and Trust

1.04%

Venture Capital

0.85%

Sovereign Wealth Fund

0.18%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

1196

63.65M

105.18%

-6.19M

2025Q1

1235

63.66M

105.15%

-6.35M

2024Q4

1202

62.66M

103.17%

-6.51M

2024Q3

1172

61.48M

99.60%

-6.16M

2024Q2

1167

61.28M

97.21%

-6.97M

2024Q1

1163

63.08M

101.15%

-2.43M

2023Q4

1156

61.76M

98.11%

-3.48M

2023Q3

1158

61.08M

96.76%

-4.05M

2023Q2

1197

61.00M

95.34%

-4.11M

2023Q1

1207

61.36M

96.91%

-3.79M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

The Vanguard Group, Inc.

5.99M

9.91%

-18.47K

-0.31%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

5.21M

8.61%

-33.38K

-0.64%

Mar 31, 2025

LSV Asset Management

2.47M

4.08%

-64.88K

-2.56%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.33M

3.85%

+293.36K

+14.42%

Mar 31, 2025

State Street Global Advisors (US)

1.97M

3.25%

-2.23K

-0.11%

Mar 31, 2025

Capital World Investors

1.93M

3.19%

+4.45K

+0.23%

Mar 31, 2025

EcoR1 Capital, LLC

1.71M

2.82%

--

Mar 31, 2025

JP Morgan Asset Management

1.50M

2.48%

+71.69K

+5.01%

Mar 31, 2025

Columbia Threadneedle Investments (US)

1.35M

2.24%

-136.12K

-9.14%

Mar 31, 2025

Fuller & Thaler Asset Management Inc.

1.33M

2.2%

+391.66K

+41.69%

Mar 31, 2025

115.315USD

Jazz Pharmaceuticals PLC

115.315

개요

회사

금융